SNDX-5613 (Synonyms: SNDX-5613) |
Katalog-Nr.GC39508 |
SNDX-5613 ist ein potenter und spezifischer Menin-MLL-Inhibitor mit einem Bindungs-Ki von 0,149 nM und einem zellbasierten IC50 von 10-20 nM. SNDX-5613 kann fÜr die Erforschung akuter MLL-rearrangierter (MLL-r) LeukÄmien, einschließlich akuter lymphoblastischer LeukÄmie (ALL) und akuter myeloischer LeukÄmie (AML), verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2169919-21-3
Sample solution is provided at 25 µL, 10mM.
SNDX-5613 is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. SNDX-5613 can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)[1].
[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
Average Rating: 5
(Based on Reviews and 40 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *